company background image
BMRA

Biomerica NasdaqCM:BMRA Stock Report

Last Price

US$3.34

Market Cap

US$42.9m

7D

14.4%

1Y

-8.5%

Updated

28 May, 2022

Data

Company Financials
BMRA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

BMRA Stock Overview

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide.

Biomerica Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biomerica
Historical stock prices
Current Share PriceUS$3.34
52 Week HighUS$7.38
52 Week LowUS$2.65
Beta-0.51
1 Month Change-16.08%
3 Month Change-17.53%
1 Year Change-8.49%
3 Year Change48.44%
5 Year Change32.54%
Change since IPO-4.57%

Recent News & Updates

Dec 03
Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable

Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable

Despite strong share price growth of 66% for Biomerica, Inc. ( NASDAQ:BMRA ) over the last few years, earnings growth...

Shareholder Returns

BMRAUS Medical EquipmentUS Market
7D14.4%2.9%6.2%
1Y-8.5%-14.9%-11.4%

Return vs Industry: BMRA exceeded the US Medical Equipment industry which returned -14.9% over the past year.

Return vs Market: BMRA exceeded the US Market which returned -10.2% over the past year.

Price Volatility

Is BMRA's price volatile compared to industry and market?
BMRA volatility
BMRA Average Weekly Movement9.5%
Medical Equipment Industry Average Movement10.5%
Market Average Movement7.8%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market2.8%

Stable Share Price: BMRA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: BMRA's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
197166Zack Iranihttps://www.biomerica.com

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company’s diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient’s body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories.

Biomerica Fundamentals Summary

How do Biomerica's earnings and revenue compare to its market cap?
BMRA fundamental statistics
Market CapUS$42.93m
Earnings (TTM)-US$3.51m
Revenue (TTM)US$14.62m

2.9x

P/S Ratio

-12.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BMRA income statement (TTM)
RevenueUS$14.62m
Cost of RevenueUS$12.12m
Gross ProfitUS$2.50m
Other ExpensesUS$6.01m
Earnings-US$3.51m

Last Reported Earnings

Feb 28, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.27
Gross Margin17.09%
Net Profit Margin-23.98%
Debt/Equity Ratio0%

How did BMRA perform over the long term?

See historical performance and comparison

Valuation

Is Biomerica undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: BMRA ($3.34) is trading below our estimate of fair value ($13.31)

Significantly Below Fair Value: BMRA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BMRA is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Medical Equipment industry average.

PE vs Market: BMRA is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BMRA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BMRA is overvalued based on its Price-To-Book Ratio (4.4x) compared to the US Medical Equipment industry average (2.5x).


Future Growth

How is Biomerica forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


15.9%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biomerica has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Biomerica performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-34.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BMRA is currently unprofitable.

Growing Profit Margin: BMRA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BMRA is unprofitable, and losses have increased over the past 5 years at a rate of 34.1% per year.

Accelerating Growth: Unable to compare BMRA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BMRA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.1%).


Return on Equity

High ROE: BMRA has a negative Return on Equity (-35.93%), as it is currently unprofitable.


Financial Health

How is Biomerica's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BMRA's short term assets ($15.2M) exceed its short term liabilities ($6.7M).

Long Term Liabilities: BMRA's short term assets ($15.2M) exceed its long term liabilities ($1.1M).


Debt to Equity History and Analysis

Debt Level: BMRA is debt free.

Reducing Debt: BMRA had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable BMRA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: BMRA is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 28.3% per year.


Dividend

What is Biomerica current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BMRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BMRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BMRA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BMRA's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BMRA has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Zack Irani (55 yo)

25.08yrs

Tenure

US$488,334

Compensation

Mr. Zackary S. Irani, also known as Zack, has been Chairman of the Board and Chief Executive Officer of Biomerica Inc. since April 29, 1997 and served as its President. Mr. Irani serves as the President an...


CEO Compensation Analysis

Compensation vs Market: Zack's total compensation ($USD488.33K) is below average for companies of similar size in the US market ($USD759.98K).

Compensation vs Earnings: Zack's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: BMRA's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: BMRA's board of directors are considered experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.5%.


Top Shareholders

Company Information

Biomerica, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Biomerica, Inc.
  • Ticker: BMRA
  • Exchange: NasdaqCM
  • Founded: 1971
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$42.925m
  • Shares outstanding: 12.85m
  • Website: https://www.biomerica.com

Number of Employees


Location

  • Biomerica, Inc.
  • 17571 Von Karman Avenue
  • Irvine
  • California
  • 92614
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/28 00:00
End of Day Share Price2022/05/27 00:00
Earnings2022/02/28
Annual Earnings2021/05/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.